GE Healthcare, a unit of General Electric Company, is launching Biacore 4000, a powerful solution for large-scale, label-free molecular interaction analysis in drug discovery, from early screening to characterization.
Biacore 4000 delivers high quality binding, kinetic, affinity, concentration, and specificity data in both screening assays and detailed characterization studies. The system is designed for large-scale parallel interaction analyses, with the capability to analyze up to 4800 interactions in 24hrs. Biacore 4000 is supported by dedicated software packages for the key drug discovery application areas of small molecule discovery, and antibody screening and characterization, which fully exploit the capabilities of the system.
In combination with the LMW Extension Package software, the Biacore 4000 delivers the sensitivity, throughput and high quality data required for fragment screening, lead selection, and optimization. The system rapidly discriminates between well behaved and promiscuous/atypical binders and presents streamlined, customized data evaluation. Additional kinetic fitting models provide increased flexibility for compound-interaction analysis. Data generated can be easily exported for customized analysis and workflow integration.
The Antibody Extension Package enables Biacore 4000 users to get the best out of their system for antibody analysis applications, saving time and reagents in biotherapeutic development. Dedicated software tools for high throughput kinetic studies and epitope mapping enable rapid identification of promising candidates. Decision-critical kinetic information is generated twice as fast as with traditional multi-cycle kinetic assays, using the 2-over-2 kinetic approach.
Dr. Paul Leonard, Principal Investigator at the Biomedical Diagnostics Institute, Dublin City University, said: “Providing excellent data quality with unparalleled throughput, Biacore 4000 has become an essential tool in our organisation for the selection of application-tailored antibodies for diagnostic applications.”
Date: February 11, 2010
Source: GE Healthcare
Filed Under: Drug Discovery
